Not a good buy right now for an impatient entry: near-term momentum is weakening (MACD negative/expanding) and short-term pattern stats lean bearish for the next week.
Longer-term backdrop is constructive (bullish MA stack, hedge funds buying heavily, multiple price-target raises), but the current tape suggests a better entry may appear closer to support (~67.2) or after momentum turns up.
RSI: RSI_6 ~46 = neutral, no oversold bounce signal.
Key levels: Price ~69.16 is slightly below pivot 69.995; downside support S1 ~67.21 then S2 ~65.49; resistance R1 ~72.78 then R2 ~74.50.
Pattern/near-term expectation (provided): ~50% chance of small move next day, but skew points to weakness over the next week (-3.78%).
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Sentiment mixed: OI put/call 0.72 leans bullish positioning overall, but today’s put/call volume 1.33 suggests more near-term hedging/speculation to the downside.
Activity/attention elevated vs baseline: today volume vs 30-day avg ~10.72x (headline flow/positioning into upcoming events).
Volatility: 30D IV 67.66 vs historical vol 35.13 = options are pricing a larger-than-normal move (often seen into catalysts like earnings); IV percentile ~49 (mid-range), IV rank ~18.7 (not extreme vs its own history).
Technical Summary
Sell
3
Buy
9
Positive Catalysts
on 2026-02-23 pre-market (can re-rate the stock if guidance/GM trajectory improves).
Neutral/Negative Catalysts
Near-term technical momentum is deteriorating (MACD negative and worsening) while price sits just below pivot—raises odds of a support test (~67.2).
Options volume skew is bearish (put/call volume 1.33), consistent with short-term caution.
Gross margin: 39.54%, down 2.63% YoY (watch for margin stabilization/expansion in upcoming quarters, especially into QDEC 2025 earnings).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: price targets have been moving up in early 2026 (Piper to $87; Wells to $82; earlier Wells to $70; BofA to $67). Tone has improved alongside “easing comps” and consumer outlook optimism.
Offsetting moves: Deutsche downgraded to Hold (wait-and-see on staples/SMID volatility); Morgan Stanley initiated Equal Weight ($71) citing near-term macro pressures.
Wall Street “pros” view: secular category growth + company positioning; potential 2026 demand tailwinds; valuation seen as reset/attractive by bulls.
Wall Street “cons” view: near-term consumer/macro constraints and uncertainty; margin pressure (GM down YoY); some firms prefer to wait for clearer fundamental inflection.
Wall Street analysts forecast FRPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FRPT is 68.11 USD with a low forecast of 61 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast FRPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FRPT is 68.11 USD with a low forecast of 61 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 67.370
Low
61
Averages
68.11
High
80
Current: 67.370
Low
61
Averages
68.11
High
80
Piper Sandler
Overweight
maintain
$80 -> $87
AI Analysis
2026-02-04
New
Reason
Piper Sandler
Price Target
$80 -> $87
AI Analysis
2026-02-04
New
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Freshpet to $87 from $80 and keeps an Overweight rating on the shares. The firm believes Freshpet is likely a beneficiary of stronger middle- and high-income consumers' tax savings and elevated 2026 refunds. Piper views this as a catalyst to accelerate revenue growth in 2026, if Freshpet benefits from higher tax refunds/lower withholding, as it expects.
Wells Fargo
Overweight
maintain
$70 -> $82
2026-01-26
Reason
Wells Fargo
Price Target
$70 -> $82
2026-01-26
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Freshpet to $82 from $70 and keeps an Overweight rating on the shares. The firm thinks Freshpet screens favorably with easing comparisons through FY26 plus prospects for better a consumer, and valuation reset near historical lows. Wells recommends buying into recent momentum.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FRPT
